e We compared the ability of the EUCAST EDef 7.2 and the Etest to detect the susceptibility to micafungin of 160 Candida and non-Candida clinical isolates. Agreement was higher when Etest MICs were obtained after 24 h of incubation; essential agreement was 90%, and categorical agreement was >90%. False susceptibility was seen only for Candida krusei (10%), and false resistance was observed in 6% of the isolates, ranging from 2.6% (C. glabrata) to 13% (C. albicans).
T
he CLSI M27-A3 and EUCAST broth microdilution procedures are the gold standard for antifungal susceptibility testing and can detect micafungin-resistant isolates (1) (2) (3) (4) (5) (6) . These procedures are comparable, and the results obtained correlated with clinical outcome (7) (8) (9) . However, they are time-consuming and difficult to implement in clinical microbiology laboratories.
The Etest (bioMérieux) is a fast and cost-effective alternative, and agreement with CLSI M27-A3 is high when testing the susceptibility of Candida spp. to micafungin (10) (11) (12) . Agreement between the Etest and the EUCAST procedure is also high for caspofungin (13, 14) . We compared for the first time EUCAST and the Etest for detection of susceptibility to micafungin in a collection of Candida isolates.
Organisms and identification. We studied 160 yeast strains obtained from patients with fungemia admitted to Gregorio Marañón Hospital (2007 to 2013) ( Table 1 ). The 17 control isolates (5 strains with fks hot spot [HS] mutations and 12 intrinsically echinocandin-resistant non-Candida isolates) were included in the analysis (Tables 1 and 2) .
Antifungal susceptibility testing. The in vitro susceptibility was obtained by means of the EUCAST and the Etest methods. For EUCAST EDef 7.2., the plates were incubated for 24 h at 35°C, and MIC values were determined spectrophotometrically at 530 nm (15, 16) ; a minimum threshold of optical density of Ն0.3 was used for growth control wells to validate the reading of the plates. NonCandida isolates were incubated with shaking at 30°C. All MICs could be obtained after 24 h of incubation. Candida krusei ATCC 6258 and C. parapsilosis ATCC 22019 were used as quality control strains.
Etest strips containing micafungin at concentrations ranging from 0.002 to 32 g/ml were used. The plates were incubated at 35°C and read after 24 h and 48 h of incubation. The MIC value was defined as the lowest concentration of micafungin at which the zone of inhibition intersects the strip; microcolonies in the inhibition zone were not taken into account.
Identification of fks mutations. HS1 and HS2 from the fks genes of the 5 Candida control isolates were amplified as previously described (17) (18) (19) (Table 2 ). The presence of fks mutations (23); the distribution of isolates was as follows: C. albicans, n ϭ 31; C. parapsilosis complex, n ϭ 27 (C. parapsilosis sensu stricto, n ϭ 24; C. orthopsilosis, n ϭ 3); C. glabrata, n ϭ 40; C. krusei, n ϭ 10; C. tropicalis, n ϭ 28; Candida spp., n ϭ 12 (C. dubliniensis, n ϭ 5; C. guilliermondii, n ϭ 4; C. kefyr, n ϭ 1; C. lusitaniae, n ϭ 1; Pichia caribbica, n ϭ 1); and other yeasts, n ϭ 12 (Rhodotorula mucilaginosa, n ϭ 7; Trichosporon spp., n ϭ 5).
was also screened in the remaining isolates showing phenotypic resistance.
Comparison between procedures. Off-scale results obtained using the Etest were transformed to the next higher dilution matching the scale used for the EUCAST procedure. Using the MICs obtained by the EUCAST procedure after 24 h of incubation as the gold standard, the results obtained by Etest after 24 h and 48 h of incubation were studied. MIC discrepancies of no more than Ϯ2-fold dilutions were used to calculate the essential agreement (EA) (20, 21) . Categorical agreement (CA) was analyzed using the following species-specific clinical breakpoints: Ն0.031 g/ml (C. albicans), Ն4 g/ml (C. parapsilosis), or Ն0.062 g/ml (C. glabrata) (22) . For C. tropicalis and C. krusei, we chose epidemiological cutoff values (ECOFFs) of Ն0.125 and Ն0.5 g/ml, respectively (22) , for defining non-wild-type isolates.
We considered discrepancies to be very major errors (VMEs) or false susceptibility when the Etest classified a strain as susceptible and the EUCAST procedure classified the strain as resistant and to be major errors (MEs) or false resistance when a strain was classified as resistant by the Etest method and susceptible by the EUCAST procedure. Table 1 shows the susceptibilities of the 160 isolates to micafungin. The EA between the two procedures was high (Table 3) . After 48 h of incubation, agreement decreased for all species; for C. parapsilosis, growth was slow. The overall CA was high, although differences were found between species (Table 4) . No VMEs were seen for most of the species studied after 24 h of incubation, with the exception of C. krusei. The Etest correctly classified as resistant the 5 isolates with mutations in the fks genes and the 12 intrinsically micafungin-resistant non-Candida isolates.
In previous studies, the EA between the Etest and EUCAST for caspofungin ranged from 87.7% (13) to 94% (14) . Unfortunately, no CA was reported in either study. As with the results reported for caspofungin in previous studies, we found that the EA between the Etest and the EUCAST procedure for micafungin was very high after 24 h of incubation. However, 17% of the strains studied did not grow properly, and the Etest had to be read after 48 h of incubation. This delay could be a limitation of the Etest, particularly for C. parapsilosis isolates.
The CA was also high, but the percentage of errors was species dependent and lower when the Etest was read after 24 h. Of interest, VMEs were infrequent and were seen only with C. krusei (involving 10% of isolates) or with C. tropicalis only after 48 h of incubation. The presence of a VME for C. krusei with micafungin is a matter of concern owing to its intrinsic resistance to fluconazole.
The overall rate of MEs was 6%, ranging from 2.6% (C. glabrata) to 13% (C. albicans) after 24 h of incubation. The presence of MEs could necessitate the use of an alternative antifungal agent to the echinocandins. However, impact would be limited in the case of C. albicans, as most isolates are fluconazole susceptible. The impact could also be negative for C. glabrata, as many clinicians prefer echinocandins to fluconazole. We did not find mutations in the 15 isolates (C. albicans, n ϭ 10; C. glabrata, n ϭ 3; C. tropicalis, n ϭ 1; C. krusei, n ϭ 1) showing phenotypic resistance by the EUCAST procedure (n ϭ 1), Etest (n ϭ 11), or both (n ϭ 3). Our study is limited by the low number of micafungin-resistant and C. krusei isolates. Furthermore, all isolates came from a single hospital. Further studies should be carried out to prove whether higher micafungin MICs in the Etest are an intrinsic problem of C. krusei and C. tropicalis. However, we did include control isolates with well-characterized micafungin resistance mechanisms.
To conclude, we found that the Etest was an effective procedure when screening for the presence of micafungin-resistant Candida isolates if results were obtained after 24 h of incubation. Resistant strains, particularly of C. albicans, should be retested using a broth microdilution procedure in order to prove resistance to micafungin. 
